Wall Street analysts expect Trustmark (TRMK) to post quarterly earnings of $0.86 per share in its upcoming report, which indicates a year-over-year increase of 30.3%. Revenues are expected to be $201.33 million, up 8.3% from the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Before a company reveals its earnings, it i ...

Company Overview - Belden's shares increased by 3.6% to close at $130.81, with notable trading volume compared to typical sessions, and a total gain of 15.4% over the past four weeks [1] - In Q1 2025, Belden's revenues rose by 16.6% year-over-year to $625 million, surpassing the Zacks Consensus Estimate of $613 million, while adjusted earnings per share (EPS) were $1.60, exceeding the estimate of $1.48, marking a 29% year-over-year increase [2] - The upcoming quarterly earnings report is expected to show EPS of $1.72, reflecting a year-over-year increase of 13.9%, with revenues projected at $653 million, an 8.1% increase from the previous year [3] Earnings Estimates and Market Position - The consensus EPS estimate for Belden has remained unchanged over the last 30 days, indicating that stock price movements may not continue without trends in earnings estimate revisions [4] - Belden holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook, while another company in the same industry, Atkore Inc., also holds a Zacks Rank of 3 and has seen a 3.4% increase in its stock price [4][5]

Core Viewpoint - Philip Morris is expected to report quarterly earnings of $1.85 per share, reflecting a 16.4% increase year-over-year, with revenues projected at $10.25 billion, an 8.3% increase from the previous year [1]. Earnings Projections - Analysts have revised the consensus EPS estimate 0.5% higher over the last 30 days, indicating a collective reevaluation of initial estimates [1][2]. Revenue Estimates - The estimated 'Net Revenues- Smoke-Free Excl. W&H- Total' is projected at $4.23 billion, showing a year-over-year change of +19.7% [4]. - 'Net Revenues- Combustible Tobacco- Total' is expected to reach $6.08 billion, indicating a +3.8% change from the prior-year quarter [4]. - 'Net Revenues by Geography- EA, AU & PMI DF' is forecasted at $1.77 billion, reflecting a +6.1% year-over-year change [5]. - 'Net Revenues by Geography- Europe' is anticipated to be $4.26 billion, with an +11.8% change from the previous year [5]. - 'Net Revenues by Geography- SSEA, CIS & MEA' is estimated at $2.93 billion, indicating a +5.9% change [5]. - 'Net Revenues by Geography- Americas' is projected to reach $1.33 billion, reflecting a +17.8% change from the prior-year quarter [6]. Shipment Volume Estimates - 'Shipment Volume - Cigarettes and HTUs - Total' is expected to be 195.25 billion, compared to 193.16 billion in the same quarter last year [6]. - 'Shipment Volume - EA, AU & PMI DF - Total' is projected at 27.10 billion, slightly down from 27.35 billion year-over-year [7]. - 'Shipment Volume - SSEA, CIS & MEA - Total' is expected to be 95.56 billion, compared to 94.33 billion in the same quarter last year [7]. - 'Shipment Volume - Americas - Total' is forecasted to reach 16.46 billion, up from 15.09 billion in the same quarter last year [8]. - 'Shipment Volume - Cigarettes and HTUs - Heated Tobacco Units' is projected at 38.37 billion, compared to 35.54 billion in the same quarter last year [8]. - 'Shipment Volume - Americas - Cigarettes' is expected to be 14.59 billion, slightly down from 14.89 billion year-over-year [9]. Market Performance - Philip Morris shares have shown a return of +0.4% over the past month, while the Zacks S&P 500 composite has changed by +4.2% [10].

Company Overview - Vertex (VERX) shares increased by 5% to close at $36.21, following a notable trading volume that exceeded typical levels, contrasting with a 6.6% loss over the past four weeks [1] - The company is benefiting from the rising adoption of e-invoicing mandates and cloud migration within the enterprise sector [1] Earnings Expectations - Vertex is projected to report quarterly earnings of $0.14 per share, reflecting a year-over-year decline of 6.7%, while revenues are expected to reach $184.25 million, marking a 14.4% increase from the previous year [2] - The consensus EPS estimate for Vertex has been revised 3% lower in the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [3] Industry Context - Vertex operates within the Zacks Internet - Software industry, where another company, Exodus Movement, Inc. (EXOD), saw its stock rise by 2.1% to $33.7, with a 5.2% return over the past month [3] - Exodus Movement, Inc. has an unchanged consensus EPS estimate of -$0.17, representing a 54.1% improvement from the previous year, but currently holds a Zacks Rank of 5 (Strong Sell) [4]

Company Overview - CRA International (CRAI) shares increased by 3% to $202.84 in the last trading session, with a notable volume of shares traded, contributing to a total gain of 9% over the past four weeks [1] - The stock is experiencing strong momentum, characterized by record-breaking performance and broad-based practice growth [1] Earnings Expectations - CRA is projected to report quarterly earnings of $1.83 per share, unchanged from the same quarter last year, with expected revenues of $179.7 million, reflecting a 4.8% increase year-over-year [2] - The consensus EPS estimate for CRA has remained stable over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Context - CRA operates within the Zacks Consulting Services industry, which includes other companies like Stantec (STN), whose shares rose by 1.2% to $111.81 in the last trading session, with a 3.5% return over the past month [4] - Stantec's consensus EPS estimate has also remained unchanged at $0.98, representing a 19.5% increase from the previous year [5]

Core Viewpoint - Analysts project Texas Capital (TCBI) will report quarterly earnings of $1.28 per share, a 60% increase year over year, with revenues expected to reach $298.24 million, an 11.7% increase from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised downward by 0.7% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Key Financial Metrics - Analysts estimate the 'Efficiency Ratio' to be 66.6%, down from 70.6% a year ago [4]. - The 'Net Interest Margin' is expected to be 3.2%, up from 3.0% in the same quarter last year [5]. - The 'Average Balance - Total earning assets' is projected at $30.98 billion, compared to $28.57 billion a year ago [5]. - 'Total Non-Performing Assets' are estimated at $96.88 million, up from $85.02 million a year ago [5][6]. Income Projections - 'Net Interest Income' is forecasted to reach $245.58 million, compared to $216.58 million last year [6]. - 'Total Non-Interest Income' is expected to be $52.56 million, up from $50.42 million a year ago [6]. - 'Net Interest Income (FTE)' is estimated at $246.85 million, compared to $216.65 million in the same quarter last year [7]. - 'Wealth Management and Trust Fee Income' is projected at $4.02 million, up from $3.70 million last year [7]. Additional Income Metrics - 'Service Charges on Deposit Accounts' are expected to reach $8.12 million, compared to $5.91 million a year ago [8]. - 'Other Non-Interest Income' is projected at $8.22 million, up from $7.99 million last year [8]. - 'Trading Income' is expected to be $6.12 million, compared to $5.65 million in the same quarter last year [9]. Stock Performance - Texas Capital shares have returned +14.6% over the past month, outperforming the Zacks S&P 500 composite's +4% change [9].

Core Viewpoint - South Plains Financial (SPFI) is expected to report quarterly earnings of $0.77 per share, a 16.7% increase year-over-year, with revenues projected at $51.7 million, reflecting a 6.4% growth compared to the previous year [1]. Earnings Projections - The consensus EPS estimate has been revised 2.4% lower in the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Key Financial Metrics - The consensus estimate for the 'Efficiency ratio' is 64.7%, down from 66.7% a year ago [5]. - 'Nonperforming Loans' are expected to reach $7.70 million, a significant decrease from $23.45 million reported in the same quarter last year [5]. - 'Net Interest Margin (FTE)' is forecasted at 3.8%, up from 3.6% in the same quarter of the previous year [5]. - 'Average Balance - Total interest-earning assets' is estimated at $4.15 billion, compared to $4.00 billion reported last year [6]. - 'Net Interest Income' is projected at $39.59 million, an increase from $35.89 million reported in the same quarter last year [6][7]. - 'Total Noninterest Income' is expected to be $12.11 million, slightly down from $12.71 million a year ago [7]. Stock Performance - Over the past month, shares of South Plains Financial have returned +2.7%, while the Zacks S&P 500 composite has changed by +4.1% [7]. - Currently, SPFI holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the overall market in the near future [7].

Core Viewpoint - Analysts project that M&T Bank Corporation (MTB) will report quarterly earnings of $4.03 per share, a 6.3% increase year over year, with revenues expected to reach $2.39 billion, up 3.6% from the same quarter last year [1]. Earnings Projections - The consensus EPS estimate has been revised down by 0.2% in the past 30 days, indicating a reassessment by covering analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Key Financial Metrics - Analysts forecast the 'Efficiency Ratio' to be 56.3%, compared to 55.3% a year ago [4]. - The 'Net Interest Margin' is expected to reach 3.7%, up from 3.6% in the same quarter last year [5]. - The 'Average Balance - Total Earning Assets' is projected at $191.73 billion, down from $193.68 billion year over year [5]. - The 'Tier 1 Leverage' is estimated at 10.1%, slightly up from 10.0% a year ago [5]. - The 'Tier 1 Capital Ratio' is expected to be 12.9%, down from 13.2% year over year [6]. - The 'Total Capital Ratio' is projected at 14.6%, compared to 14.9% a year ago [6]. - 'Total Other Income' is estimated at $638.93 million, up from $584.00 million year over year [6]. Revenue Estimates - The consensus for 'Net Interest Income - Taxable-Equivalent' stands at $1.76 billion, compared to $1.73 billion in the same quarter last year [7]. - 'Service Charges on Deposit Accounts' are estimated at $135.70 million, up from $127.00 million year over year [7]. - 'Trust Income' is projected to reach $181.34 million, compared to $170.00 million in the same quarter last year [8]. - 'Mortgage Banking Revenues' are expected to be $126.99 million, up from $106.00 million year over year [8]. - 'Net Interest Income' is anticipated to be $1.74 billion, compared to $1.72 billion a year ago [9]. Stock Performance - Over the past month, M&T Bank shares have returned +10.9%, outperforming the Zacks S&P 500 composite's +4.1% change [9].

Core Viewpoint - Progressive (PGR) is expected to report significant growth in earnings and revenues for the upcoming quarter, with analysts predicting earnings of $4.30 per share, a 62.3% increase year-over-year, and revenues of $21.52 billion, reflecting a 17.9% increase [1]. Earnings Projections - The consensus EPS estimate has been revised 1.1% higher in the last 30 days, indicating a collective reevaluation by analysts [2]. - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3]. Revenue and Key Metrics - Analysts forecast 'Service revenues' at $128.06 million, a year-over-year increase of 20.5% [5]. - 'Net premiums earned' are expected to be $20.19 billion, reflecting a 17.3% increase from the prior year [5]. - 'Investment income' is projected to reach $860.70 million, indicating a year-over-year change of 25.7% [5]. Expense and Combined Ratios - 'Net premiums earned - Commercial Lines' are estimated at $2.78 billion, a 4.3% year-over-year change [6]. - The 'Companywide Total - Expense ratio' is projected at 19.7%, up from 19.0% in the same quarter last year [6]. - The 'Companywide Total - Combined ratio' is expected to be 88.7%, compared to 91.9% a year ago [6]. Loss Ratios - The 'Companywide Total - Loss/LAE ratio' is forecasted to be 68.9%, down from 72.9% in the previous year [7]. - The 'Property Business - Combined ratio' is expected to reach 107.3%, significantly improved from 166.3% in the same quarter last year [7]. Business Segment Insights - The 'Commercial Lines Business - Combined ratio' is estimated at 89.9%, slightly higher than the year-ago figure of 88.6% [8]. - The 'Property Business - Loss/LAE ratio' is projected to be 78.3%, down from 137.4% a year ago [8]. - The 'Property Business - Expense ratio' is expected to be 29.0%, compared to 28.9% in the previous year [8]. Stock Performance - Over the past month, Progressive shares have declined by 7.1%, contrasting with the S&P 500 composite's increase of 4.1% [9].

Company Overview - Rhythm Pharmaceuticals, Inc. (RYTM) shares increased by 36.6% in the last trading session, closing at $89, with notable trading volume compared to typical sessions [1] - The stock had previously experienced a 3.3% loss over the past four weeks [1] Recent Developments - The stock's rally followed the announcement of positive top-line data from a phase II study of the investigational oral melanocortin-4 receptor (MC4R) agonist, bivamelagon, for patients with acquired hypothalamic obesity [2] - The study results indicated statistically significant and clinically meaningful reductions in body mass index after 14 weeks of treatment with bivamelagon [2] Financial Expectations - The company is projected to report a quarterly loss of $0.64 per share, reflecting a year-over-year change of -16.4% [3] - Expected revenues for the upcoming report are $43.76 million, which represents a 50.5% increase from the same quarter last year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not continue without trends in earnings estimate revisions [4] Industry Context - Rhythm Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like EyePoint Pharmaceuticals (EYPT) [5] - EYPT shares closed 10.2% higher at $10.96, with an 8% return over the past month [5] - EYPT's consensus EPS estimate for the upcoming report has also remained unchanged at -$0.67, representing a -15.5% change from the previous year [6]